GT Biopharma (NASDAQ:GTBP) Now Covered by Analysts at Roth Mkm

Roth Mkm started coverage on shares of GT Biopharma (NASDAQ:GTBP) in a report published on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $11.00 price target on the stock.

GT Biopharma Stock Down 0.4 %

GTBP opened at $2.79 on Monday. GT Biopharma has a 12 month low of $1.92 and a 12 month high of $10.66. The firm’s fifty day simple moving average is $2.66 and its 200 day simple moving average is $2.74.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.